Neuren Pharmaceuticals Limited

ASX:NEU 주식 보고서

시가총액: AU$1.7b

Neuren Pharmaceuticals 미래 성장

Future 기준 확인 0/6

Neuren Pharmaceuticals 의 수익과 수익은 각각 연간 2.6% 및 9.9% 감소할 것으로 예상됩니다. EPS는 연간 14.1% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 19% 로 예상됩니다.

주요 정보

-9.9%

수익 성장률

-14.1%

EPS 성장률

Pharmaceuticals 수익 성장46.2%
매출 성장률-2.6%
향후 자기자본 수익률19.0%
애널리스트 커버리지

Good

마지막 업데이트18 Nov 2024

최근 미래 성장 업데이트

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 29
Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Nov 11
New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Nov 08
Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Oct 24
Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 29
Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Aug 14
Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

May 31
Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

May 03
Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01
An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05
Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02
Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18
Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02
Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31
Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03
This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31
Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03
We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06
Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19
Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Jan 04
Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

수익 및 매출 성장 예측

ASX:NEU - 애널리스트의 미래 추정치 및 과거 재무 데이터 (AUD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2026209109103885
12/31/202511458115876
12/31/202419411336695
6/30/2024193117119120N/A
3/31/2024213137152152N/A
12/31/2023232157185185N/A
9/30/2023155106120120N/A
6/30/202378555454N/A
3/31/202347282929N/A
12/31/202215044N/A
9/30/20229-3-3-3N/A
6/30/20223-7-10-10N/A
3/31/20223-7-10-10N/A
12/31/20213-8-10-10N/A
9/30/20212-10-10-10N/A
6/30/20211-12-9-9N/A
3/31/20211-11-9-9N/A
12/31/20201-9-8-8N/A
9/30/20201-8-9-9N/A
6/30/20200-8-9-9N/A
3/31/20200-9-10-10N/A
12/31/20190-11-12-12N/A
9/30/20197-6-5-5N/A
6/30/201914-122N/A
3/31/201914144N/A
12/31/201814366N/A
9/30/20187300N/A
6/30/201813-6-6N/A
3/31/201813N/A-6N/A
12/31/201713N/A-6N/A
9/30/20172-2N/A-7N/A
6/30/20173-8N/A-8N/A
3/31/20173-10N/A-10N/A
12/31/20163-12N/A-12N/A
9/30/20162-14N/A-14N/A
6/30/20160-15N/A-17N/A
3/31/20161-14N/A-15N/A
12/31/20152-13N/A-13N/A
9/30/20152-11N/A-11N/A
6/30/20153-9N/A-8N/A
3/31/20153-9N/A-7N/A
12/31/20143-8N/A-6N/A
9/30/20143-10N/A-7N/A
6/30/20143-12N/A-7N/A
3/31/20144-11N/A-7N/A
12/31/20135-10N/A-7N/A

애널리스트 미래 성장 예측

수입 대 저축률: NEU 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -9.9% ).

수익 vs 시장: NEU 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -9.9% ).

고성장 수익: NEU 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: NEU 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -2.6% ).

고성장 수익: NEU 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -2.6% ).


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: NEU 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 19 %).


성장 기업 발견